反应详情

2-(6-Chloro-1-(isoxazol-3-ylmethyl)-1H-indazol-3-yl)-N-isopropyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide was dissolved in dichloromethane and to this was added trifluoroacetic acid (1.79 g, 1.21 mL, 15.7 mmol). The mixture was stirred for 120 h. A precipitate had formed which was filtered off. The filtrates were concentrated in vacuo and combined with the solid to give intermediate 2-(6-chloro-1-(isoxazol-3-ylmethyl)-1H-indazol-3-yl)-5-(hydroxymethyl)-N-isopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (73 mg, 157 μmol). This was dissolved in 60:20:1 dichloromethane:methanol:ammonium hydroxide (10 mL), and the mixture was stirred for 2 h. The mixture was concentrated in vacuo, diluted with dichloromethane and reconcentrated to give 2-(6-chloro-1-(isoxazol-3-ylmethyl)-1H-indazol-3-yl)-N-isopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (67 mg, 154 μmol, 98.1%) as a white solid. MS (M+Na)+=458; 1H NMR (CDCl3) δ: 11.97 (br. s., 1H), 9.08 (s, 1H), 8.36 (d, J=8.3 Hz, 1H), 8.29 (d, J=1.5 Hz, 1H), 8.16 (d, J=3.0 Hz, 1H), 7.98-8.07 (m, 1H), 7.46 (s, 1H), 7.12 (dd, J=8.5, 1.3 Hz, 1H), 6.21 (d, J=1.5 Hz, 1H), 5.64 (s, 2H), 4.23-4.39 (m, 1H), 1.20-1.32 (m, 6H).

1. customA precipitate had formed which
2. filtrationwas filtered off
3. concentrationThe filtrates were concentrated in vacuo